Prot #R668-EGE-2213: A Phase 2/3, Randomized, 3-part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Gastritis with or without Eosinophilic Duodenitis

Project: Research project

Project Details

StatusActive
Effective start/end date8/2/24 → 8/2/27

Funding

  • ICON Clinical Research Limited (Prot #R668-EGE-2213 // Prot #R668-EGE-2213)
  • Regeneron Pharmaceuticals, Inc. (Prot #R668-EGE-2213 // Prot #R668-EGE-2213)